Reviewing Palisade Bio (NASDAQ:PALI) and GSK (NYSE:GSK)

Palisade Bio (NASDAQ:PALI) and GSK (NYSE:GSK) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Volatility & Risk

Palisade Bio has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Palisade Bio and GSK, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1	0	8	2	3.00
GSK	3	13	3	0	2.00

Palisade Bio currently has a consensus target price of $9.29, indicating a potential upside of 700.49%. GSK has a consensus target price of $56.30, indicating a potential upside of 13.78%. Given Palisade Bio’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Palisade Bio is more favorable than GSK.

Profitability

This table compares Palisade Bio and GSK’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
GSK	13.00%	41.41%	11.09%

Institutional and Insider Ownership

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Palisade Bio and GSK”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$500,000.00	404.31	-$16.78 million	($0.48)	-2.42
GSK	$43.07 billion	2.32	$7.54 billion	$2.88	17.18

GSK has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Summary

GSK beats Palisade Bio on 9 of the 15 factors compared between the two stocks.

About Palisade Bio

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.